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ABSTRACT
Objectives: Pancreatic ductal adenocarcinoma (PDAC)
and biliary tract cancers (BTC) are often diagnosed late
and at an advanced stage. Population-based screening
programmes do not exist and diagnosis is primarily
dependent on symptom recognition. Recently
symptom-based cancer decision support tools (CDSTs)
have been introduced into primary care practices
throughout the UK to support general practitioners
(GPs) in identifying patients with suspected PDAC.
However, future refinement of these tools to improve
their diagnostic accuracy is likely to be necessary.
Setting: The Health Improvement Network (THIN) is a
primary care database, which includes more than 11
million electronic patient records, from 562 GP
practices in the UK.
Participants: All patients with a diagnosis of PDAC or
BTC between 2000 and 2010 were included in the study
along with six matched controls; 2773 patients with
PDAC, 848 patients with BTC and 15 395 controls.
Primary and secondary outcome measures: The
primary aim of this study was to determine the early
symptom profiles of PDAC and BTC. Secondary aims
included comparing early symptom trends between BTC
and PDAC, defining symptom onset in PDAC and
evaluating trends in routine blood tests nearest to the
time of diagnosis.
Results: In the year prior to diagnosis, patients with
PDAC visited their GP on a median of 18 (IQR 11–27)
occasions. PDAC was associated with 11 alarm
symptoms and BTC with 8. Back pain (OR 1.33 (95% CI
1.18 to 1.49) p<0.001), lethargy (1.42 (95% CI 1.25 to
1.62) p<0.001) and new onset diabetes (OR 2.46 (95%
CI 2.16 to 2.80)) were identified as unique features of
PDAC.
Conclusions: PDAC and BTC are associated with
numerous early alarm symptoms. CDSTs are therefore
likely to be useful in identifying these tumours at an
early stage. Inclusion of unique symptoms, symptoms
with an early onset and routinely performed blood tests
is likely to further improve the sensitivity of these tools.
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC)
and biliary tract cancers (BTC) are lethal
tumours that are often diagnosed late when
the disease is at an advanced stage and no
longer amenable to curative surgical resec-
tion.1 2 PDAC is the ninth most common
cancer in the UK with more than 8000 cases
Strengths and limitations of this study
▪ A significant strength of this study is that the
Health Improvement Network (THIN) database
includes routinely recorded primary care data
that is not subject to recall bias.
▪ The database includes a large cohort of patients
with pancreatic ductal adenocarcinoma and
biliary tract cancers (BTC).
▪ The patient population within the database has
been shown to be representative of the UK
population.
▪ This is the first study to evaluate early symptoms
of BTC in primary care.
▪ A patient’s final diagnosis within the THIN data-
base is dependent on correct coding by their
general practitioner. However, this has generally
been found to be accurate in patients with
cancer, when electronic records have been com-
pared to hospital correspondence or written
medical records.
▪ The study was limited to Read code analysis
alone. A potential concern is that additional
information is contained in the ‘free-text’ area of
the notes. Previous studies that have explored
this and have found it to only occur rarely.
▪ Currently, information about histology, stage of
disease at diagnosis or treatment received is not
linked to presenting symptoms within the THIN
database. It is therefore impossible to determine
which symptoms are associated with the earliest
stages of the disease and would therefore offer
the greatest opportunity for early intervention
and treatment. However, linkage of THIN data to
Hospital Episode Statistics (HES) data is cur-
rently underway.
▪ Although conditional logistic regression was not
utilised to take advantage of our matched data,
the study’s sample size was large enough to
make losses in statistical power negligible.
▪ The primary aim of the figures in this study was
to present a visual representation of general
trends within the data.
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diagnosed each year compared with less than 2000 cases
of BTC. Overall 5-year survival in both tumours is less
than 4%.2 3 Despite advances in diagnostic technology
and the identiﬁcation of a number of promising biomar-
kers, impact on survival has been limited and novel diag-
nostic strategies are therefore urgently needed.4
Recently prediagnostic symptom proﬁles have been
investigated as a method of enabling earlier diagnosis,
in a number of common cancers including PDAC.5 6–8
The diagnosis of PDAC is heralded by the insidious
onset of a heterogeneous collection of symptoms.
Although symptom proﬁles are recognised to vary
between patients with PDAC, certain symptoms appear
to occur with sufﬁcient frequency to be useful as early
diagnostic markers of the disease. To date, prediagnostic
symptom proﬁles for PDAC have largely been deﬁned
through postdiagnosis retrospective interview studies of
secondary care patients8 and through the interrogation
of large primary care databases with predeﬁned
symptom lists.6 7 Almost no studies have explored the
symptom proﬁle of BTC.
Deﬁning the early symptom proﬁles of PDAC has
enabled the development of symptom-based cancer deci-
sion support tools (CDSTs). Recently these tools have
been introduced into primary care practices across 15
cancer networks, throughout the UK.6 Their impact on
referral practice is subject to an ongoing audit.9 CDSTs
for PDAC have been validated independently within
other primary care data sets. Initial results suggest that
although they can effectively discriminate patients with
PDAC, they may overestimate cancer risk in certain
groups, in particular in older patients.10 Future modiﬁ-
cation of existing tools to improve their overall diagnos-
tic accuracy is therefore likely to be required.
Patients with PDAC frequently encounter a number of
delays during their route to diagnosis.11 Although PDAC
is no longer considered to be a symptomatically silent
disease, debate exists about how long patients are symp-
tomatic for and if symptoms occur simultaneously or
sequentially. A recent qualitative interview study sug-
gested very early symptoms might actually be intermit-
tent and therefore reassuring to patients leading them
to ignore them until they increase in severity or other
symptoms arise.12 Once symptomatic, large primary care
database studies and patient surveys indicate that
patients with PDAC visit their general practitioner (GP)
frequently with alarm symptoms in the months and
years prior to diagnosis.6 7 11 13 However, almost half of
patients are still diagnosed as a result of an emergency
presentation to hospital.11 Reasons why the disease is
not identiﬁed earlier are complex. The average GP will
only see one new case of PDAC every 5 years and alarm
symptoms overlap with a number of other more
common benign and malignant conditions, as a result it
is recognised as a very challenging disease to identify at
an early stage.11 Simple screening tests do not exist and
very few GPs have access to cross-sectional imaging;
therefore, diagnosis of PDAC in primary care is primarily
dependent on symptom recognition. How alarm symp-
toms for PDAC overlap with other conditions has rarely
been evaluated, and it is unclear if there are certain
symptoms or combinations of symptoms that are unique
to PDAC. In addition, very little is known about what fea-
tures of the disease prompt GPs to suspect cancer and
initiate investigations and referrals. Current National
Institute for Health and Care Excellence (NICE) refer-
ral guidelines for suspected cancer in primary care
contain limited speciﬁc information on the best method
for referring patients with suspected PDAC or BTC for
further investigation, but new guidelines are underway.14
The primary aim of this study was therefore to deter-
mine the early symptom proﬁles of PDAC and BTC in a
large primary care cohort. Secondary aims include com-
paring early symptom trends between BTC and PDAC,
deﬁning symptom onset in PDAC and evaluating trends
in routine blood tests nearest to the time of diagnosis.
METHODS
Data source
In the UK most GPs record patient data electronically. A
subset of GP practices have opted to provide anonymous
electronic patient records for use in clinical and epi-
demiological research. The Health Improvement
Network (THIN) is a primary care database, which
includes more than 11 million electronic patient
records, from 562 GP practices, covering around 6% of
the UK population (http://csdmruk.cegedim.com/).
The data are broadly representative of the UK general
practice population in terms of demographics and con-
sultation behaviour.15 16 Diagnoses, symptoms and refer-
rals to secondary care are electronically recorded using
the Read code system.17 Clinical diagnoses recorded by
GPs electronically have recently been shown to be accur-
ate compared with other reliable sources.16 18 All drug
prescriptions and variables such as body mass index
(BMI), blood pressure, smoking status, alcohol intake
and laboratory results are also recorded.
Study design
A case–control design was used to compare ‘alarm’
symptoms and commonly performed blood test results
in patients with a diagnosis of PDAC or BTC. Unaffected
controls were matched for age, sex, practice and year of
diagnosis.
Study population
All patients with a Read code diagnosis of PDAC or BTC
between 1 January 2000 and 31 December 2010 were
extracted from the database. Read code lists to identify
diagnosed patients were developed using previously
described methodology.19 The date of diagnosis was set
as the index date and for control patients a random con-
sultation date was selected to become the index date. All
patients were required to have contributed 2 years of
data prior to the index date. Two years was selected as
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the time period of interest based on preliminary data
suggesting alarm symptoms were uncommon beyond
this time period (ﬁgure 1A, B). To help ensure the data
analysed were of adequate quality, only patients from GP
practices which had achieved both acceptable mortality
recording20 and an acceptable computer usage21 were
included.
The control sample contained randomly selected
patients without a diagnosis of PDAC or BTC. Stratiﬁed
sampling within the same GP practices from where
patients with a cancer diagnosis were identiﬁed was used
to ensure control patients had similar characteristics to
those with a cancer diagnosis in terms of age, sex, prac-
tice and equivalent year of consultation (control group)
to year of diagnosis (cancer group). Up to six control
patients were selected per patient with a cancer
diagnosis.
Outcomes
Alarm symptoms and laboratory tests were selected based
on clinical knowledge and the existing literature.6 7 22–31 To
ensure that no symptoms had been missed by the literature
review, Read codes for 10% of patients with PDAC (n=296)
were reviewed in their entirety to identify any additional
common or biologically plausible symptoms (table 1). For
each individual symptom, frequency, median onset and
average number of presentations were recorded.
Symptoms were grouped according to pathological aeti-
ology and onset (greater or less than 6 months prior to
diagnosis). All symptoms with a frequency of greater than
5% were identiﬁed as potential alarm symptoms and
included in the subsequent case–control study (table 1).
Laboratory tests were restricted to routinely performed
tests to ensure adequate numbers were recorded for the
control population and included haemoglobin and liver
function tests: serum bilirubin, alkaline phosphatase
(ALP), alanine aminotransferase (ALT).
Covariates
Age, gender, time period and Townsend score, smoking
status and BMI were selected as potential confounders.
Where multiple measures of BMI and smoking status
were recorded, the earliest record in the 2-year time
frame from the index date was selected. Deprivation was
examined using quintiles of Townsend score from ‘one’
(least deprived) to ‘ﬁve’ (most deprived). The Townsend
score is a combined measure of owner occupation, car
ownership, overcrowding and unemployment based on a
patient’s postcode and linkage to population census data
for 2001 for approximately 150 households in that postal
area.
Statistical analyses
Multivariable logistic regression was used to estimate the
ORs for symptoms in the 2 years prior to PDAC or BTC
diagnosis versus the 2 years prior to the index date in
patients with and without cancer. Linear regression was
used to estimate adjusted mean differences in clinical
measures between patients with and without cancer.
Although many of these laboratory values are slightly
skewed, we decided to analyse the data without transform-
ation—the large sample size means the statistical analyses
should be robust to deviation from normality and trans-
formation can make results difﬁcult to interpret. To
account for data clustering within GP practice, we used a
multilevel regression model with the practice identiﬁer
entered as a random effect. All p values were two-tailed
and a value of less than 5% (≤0.05) was considered statis-
tically signiﬁcant. All analyses were done using Stata
V.12.1.
RESULTS
Read code analysis of a subgroup 296 patients with PDAC
The Read codes of 10% of randomly selected patients
with PDAC (296 cases) were reviewed in their entirety.
Figure 1 (A) Incidence and timing of common presenting
symptoms in 100 matched controls 1 year before a random
consultation. (B) Incidence and timing of common presenting
symptoms in 100 randomly selected patients with pancreatic
cancer in the year prior to diagnosis.
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In this group, symptoms were common (table 1); 91%
(268/296) had relevant symptoms in the 2 years prior to
diagnosis. Patients attended their GP on a median of 3
occasions with alarm symptoms (range 0–22) during this
period but visits did cluster nearest to the time of diag-
nosis (ﬁgure 1A, B). In those who were symptomatic,
51% (136/268) reattended with the same symptom
during the 2-year time period and 75% (202/268) reat-
tended with an alternative alarm symptom. Common
alarm symptoms that prompted reattendance included
abdominal, back, chest or shoulder pain, dyspepsia and
change in bowel habit. 11% (32/296) of patients had
previously been diagnosed with another cancer. The
length of time a symptom had been present for was
measured from ﬁrst presentation to time of diagnosis.
All prediagnosis serum measurements of bilirubin (345
tests), glucose (188 tests) and haemoglobin (335 tests)
were also obtained for this cohort. A rising trend in
glucose and bilirubin nearest to the time of diagnosis
was observed (ﬁgure 2).
Very few biologically plausible symptoms were reported
more than 1 year prior to diagnosis (table 1 and ﬁgure 1A,
B). The limit of the study period was therefore set at
2 years, for the subsequent case–control study.
Case–control study
In total, 2773 patients with PDAC, 848 patients with BTC
and 15 395 controls were included in this study (table 2).
In the year prior to diagnosis, patients with PDAC visited
their GP on a median of 18 (IQR 11–27) occasions and
patients with BTC visited their GP on a median of 22
(IQR 12–22) occasions. This is compared with control
patients who visited their GP on a median of 14 occasions
(IQR 8–21). In PDAC a median of three of these visits
were with alarm symptoms and a quarter visited their GP
on more than four occasions with alarm symptoms in the
year prior to diagnosis.
In the 2 years prior to diagnosis, alarm symptoms were
more common in patients with PDAC or BTC compared
with controls (table 3). For example, 43.9% of patients
Table 1 Frequency and onset of common and biologically plausible symptoms in a 10% cohort of patients with pancreatic
ductal adenocarcinoma
Symptom* N=296 (%)
Median symptom
onset—days prior
to diagnosis [range]
Mean number of presentations
with symptom prior
to diagnosis [range]
Pain
Abdominal pain 130 (44) 106 [1–1092] 1.20 [0–12]
Back pain 90 (30) 483 [7–1092] 0.54 [0–6]
Non cardiac chest pain 39 (13) 159 [10–1093] 0.18 [0–5]
Shoulder pain 21 (7) 671 [48–1095] 0.13 [0–5]
Upper GI symptoms
Dyspepsia/reflux 77 (26) 136 [12–1095] 0.52 [0–15]
Nausea and vomiting 58 (20) 73 [1–1073] 0.30 [0–13]
Abdominal mass 11 (4) 49 [0–255] 0.04 [0–1]
Bloating 9 (3) 87 [27–607] 0.00 [0–1]
Upper gastrointestinal
bleeding
8 (3) 49 [2–689] 0.00 [0–1]
Dysphagia 7 (2) 227 [0–603] 0.03 [0–1]
Hepatomegaly 3 (1) 10 [0–68] 0.01 [0–1]
Bile duct obstruction
Jaundice 104 (35) 31 [0–648] 0.35 [0–1]
Pruritus 23 (8) 114 [13–1059] 0.10 [0–5]
Lower GI symptoms
Change in bowel habit 104 (35) 188 [0–1078] 0.73 [0–14]
Pancreatic dysfunction
Pancreatitis 11 (4) 108 [21–922] 0.03 [0–1]
Steattorhoea 4 (1) 62 [0–593] 0.02 [0–1]
Other constitutional symptoms
Weight loss 29 (10) 144 [14–937] 0.09 [0–1]
Lethargy 23 (8) 219 [8–988] 0.10 [0–3]
Anorexia 14 (5) 46 [2–337] 0.00 [0–1]
DVT/PE 11 (4) 24 [0–1084] 0.04 [0–1]
Insomnia 6 (2) 45 [34–74] 0.00 [0–1]
Fracture 4 (1) 78 [0–242] 0.00 [0–1]
Change in taste/smell 2 (0.7) 40 [38–42] 0.00 [0–1]
*Each symptom was assessed independently.
[▪]=Symptom onset >6 months prior to diagnosis. [ ]=Symptom onset <6 months prior to diagnosis.
GI, gastrointestinal.
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with PDAC (OR=6.38 (95% CI 5.81 to 7.02)) and 37.3%
of patients with BTC (OR=4.68 (95% CI 4.01 to 5.47))
consulted their GP with abdominal pain compared with
just 11.3% of the control population. The incidence of
dysphagia and pain other than abdominal or back was
similar across all patient groups.
When comparing the symptom proﬁles of PDAC and
BTC, some symptoms were only a feature of PDAC such
as back pain, lethargy or new onset diabetes. However,
other alarm symptoms did overlap between both
cancers but generally were a more common feature of
one cancer than the other. For example, abdominal
pain (OR=1.35 (95% CI 1.15 to 1.59)) weight loss
(OR=2.00 (95% CI 1.49 to 2.68)) and dyspepsia
(OR=1.51 (95% CI 1.23 to 1.89)) were more frequently
associated with PDAC and jaundice (OR=0.44 (95% CI
0.34 to 0.59)), and pruritus (OR=0.57 (95% CI 0.48 to
0.66)) was more frequently associated with BTC (table
3). Symptoms of unexplained weight loss were around
twice as common in patients with PDAC compared with
patients with BTC.
Mean liver biochemical tests including serum bilirubin,
ALP and ALT closest to the date of diagnosis were substan-
tially higher in patients with PDAC and BTC compared
with controls (p<0.001; table 4). Mean serum bilirubin
levels in BTC (26.1 µmol/L) and PDAC (20.7 µmol/L)
were higher than in controls (10.2 µmol/L) but not at clin-
ically detectable levels. The mean levels of bilirubin and
ALP in patients with BTC were around double those of the
control patients. With the exception of ALP, which was sig-
niﬁcantly higher in BTC compared with PDAC (p<0.001),
there was no signiﬁcant difference in routinely performed
blood tests between the two cancer types (table 4).
BMI was signiﬁcantly lower in patients with PDAC com-
pared with patients with BTC or control patients.
However, adjustments for BMI and smoking status had no
meaningful effect on any of the relationships reported.
DISCUSSION
This study further deﬁnes the early symptom proﬁle of
PDAC and for the ﬁrst time deﬁnes early alarm
symptoms that are associated with BTC in a primary care
population. Prior to this study, very little was known
about early alarm symptoms in BTC23 24 and how they
overlapped with PDAC, although the clinical presenta-
tion of the two cancers was recognised to be similar.
Associated alarm symptoms in BTC and PDAC in this
study by and large reﬂected the underlying pathology
and correlated with disease progression (tables 1 and 3).
With the exception of jaundice, the individual ORs of
many of the associated symptoms in PDAC and BTC
were low. However, nearly all patients reported alarm
symptoms and often attended their GP on several occa-
sions in the year prior to diagnosis. To aid the earlier
diagnosis of these cancers, this study would therefore
support the development of CDSTs, which incorporate
multiple early onset, alarm symptoms.
A recent validation study of an existing CDST for
PDAC suggests it may over predict cancer risk in certain
groups including older patients.10 This has the potential
to cause unnecessary anxiety for patients and substan-
tially increase workloads in hospital departments due to
extra referrals for the investigation of patients with sus-
pected cancer. Further reﬁnement of existing tools to
improve their diagnostic accuracy is therefore likely to
be necessary.
Patients with PDAC or BTC in this study visited their
GP more frequently in the 2 years prior to diagnosis.
This reﬂected trends found in other primary care
studies7 and large patient surveys (National Cancer
Patient Experience Survey).13 A change in attendance
behaviour should therefore be considered as an alarm
feature for cancer, particularly if patients reattend with
the same alarm symptom or a constellation of alarm
symptoms.
Apart from one other retrospective secondary care
study, the length of time symptoms are present in
patients with PDAC has received little attention.8 By
comparison, pruritus appeared to be reported earlier in
this primary care cohort but other symptoms such as
change in bowel habit and anorexia were present for a
similar length of time. Previous studies measured
symptom onset in accordance with the development of
Figure 2 Trends in commonly performed blood tests in the year prior to diagnosis (bilirubin N=345 blood tests from 192
patients, glucose N=188 blood tests from 118 patients, haemoglobin N=335 blood tests from 195 patients).
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jaundice or abdominal pain rather than ﬁnal diagnosis
as in this study, which may account for some of the dis-
crepancies observed.8
Identiﬁed early symptoms of PDAC (table 1) were similar
to those identiﬁed in other primary and secondary care
studies.6–8 However, dyspepsia and pruritus have not been
identiﬁed as alarm symptoms for PDAC in primary care
patients previously.6 7 Dysphagia was identiﬁed in another
primary care study as an independent predictor of PDAC in
men,6 however it was not found to be a common early
symptom in this study. Signiﬁcant overlap occurred in the
early symptoms of PDAC and BTC and may account for why
these tumours are often difﬁcult to differentiate preopera-
tively. However, even in these two malignant conditions that
are recognised to present similarly, certain symptoms such as
back pain, lethargy and new onset diabetes were identiﬁed
as unique features of PDAC. Hence, when designing future
CDSTs, symptom overlap and the inclusion of unique symp-
toms should be a design consideration.
The frequency of alarm symptoms in this study was
similar to other primary care studies6 7 but lower than
those reported in retrospective secondary care studies.6–8
This trend has been reported before7 and may reﬂect
that there are some symptoms for which patients do not
seek medical advice. For example, anorexia and change
in taste were seen with much greater frequency in sec-
ondary care than primary care studies. If CDSTs are to be
used by patients directly in the future, further modiﬁca-
tion of these tools in line with their pre-presentation
symptom proﬁle will be necessary.
Commonly performed blood tests, in particular liver
function tests (bilirubin, ALT, ALP), often became
abnormal prior to diagnosis. These tests are frequently
performed by GPs as part of drug monitoring and
routine health checks and therefore could be included
in future algorithms.
Further guidance on the best methods of managing
patients with suspected PDAC or BTC in primary care is
also urgently needed. Current UK guidance on referring
patients with suspected PDAC or BTC from primary care is
incorporated within guidance for all upper gastrointestinal
cancers.14 These recommendations focus on the exclusion
of oesophagogastric cancer through urgent gastroscopy,
which is often normal in patients with PDAC or BTC. The
lack of speciﬁc information about recognising PDAC or
BTC and optimal methods for further investigation has
the potential to cause further delays in diagnosis. The
inclusion of more information about alarm symptoms for
PDAC and BTC, the use of CDST in routine practice and
thresholds for investigation would be particularly valuable
to GPs. Ultimately alignment of these tools to rapid assess-
ment pathways could prevent outpatients and diagnostic
services becoming overwhelmed.
CONCLUSIONS
Referrals for investigation of suspected PDAC or BTC
from primary care is currently dependent on symptom
recognition. Further deﬁnition of early alarm symptoms
associated with these two cancers by this study will
support GPs in identifying patients with suspected PDAC
or BTC. The information will also inform the future
modiﬁcation of current symptom-based CDSTs.
Widespread use of these tools in primary care is expected
to lead to patients being diagnosed at an earlier stage
when curative therapy is possible. Subsequent improve-
ments in overall survival are expected.
Table 2 Patient characteristics
Biliary tract cancer Pancreatic cancer Comparator group
n=848 (%) n=2773 (%) n=15 395 (%)
Males (%) 390 (46) 1328 (48) 7233 (47)
Mean age (±SD) 71 (12) 72 (12) 71 (11)
Mean BMI (±SD) 27 (5) 27 (5) 27 (5)
Smoking status (%)
Never 446 (53) 1345 (49) 8610 (56)
Ex 181 (21) 586 (21) 3635 (24)
Current 203 (24) 760 (27) 3090 (20)
Missing 18 (2) 82 (3) 60 (1)
Townsend score (%)
(Most affluent) 1 194 (23) 739 (27) 4176 (27)
2 197 (23) 685 (25) 3611 (24)
3 168 (20) 542 (20) 3176 (21)
4 140 (17) 457 (17) 2536 (17)
(Most deprived) 5 128 (15) 290 (11) 1542 (10)
Missing 21 (2) 60 (2) 354 (2)
Body mass index (BMI)=weight (kg)/(height(m))2.
BMI<18.5=underweight, BMI 18.5–25=normal, BMI 25–30=overweight, BMI >30=obese.
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Table 4 Liver function tests, haemoglobin levels and BMI in patients with pancreatic cancer and biliary tract cancer compared with a control population without a cancer diagnosis
Biliary tract cancer Pancreatic cancer Controls
Biliary tract cancer vs control Pancreatic cancer vs control
Pancreatic cancer vs biliary tract
cancer
Coefficient* 95% CI p Value Coefficient* 95% CI p Value Coefficient* 95% CI p Value
Bilirubin (µmol/L)
Number 628 2262 9227
Mean (±SD) 26.1 (26.5) 20.7 (23.1) 10.9 (6.2) 15.3 12.99 to 17.60 <0.001 15.3 12.99 to 17.60 <0.001 −7.4 −13.7 to −1.1 0.021
ALP (U/L)
Number 615 2220 9412
Mean (±SD) 183.7 (107) 152.2 (95.9) 93.8 (48) 89.8 81.0 to 98.5 <0.001 89.8 81.0 to 98.5 <0.001 −63.6 −95.4 to −31.8 <0.001
ALT (U/L)
Number 490 1719 7730
Mean (±SD) 37.3 (24.5) 31.4 (20.7) 24.4 (12.8) 13.39 11.14 to 15.64 <0.001 13.39 11.14 to 15.64 <0.001 −3.1 −11.7 to 5.6 0.486
Haemoglobin (g/dL)
Number 727 2602 9331
Mean (±SD) 12.9 (1.8) 13 (1.7) 13.5 (1.6) −0.62 −0.75 to −0.48 <0.001 −0.62 −0.75 to −0.48 <0.001 0.4 −0.4 to 1.3 0.33
BMI
Number 608 2297 9316
Mean (±SD) 26.6 (5.2) 25.6 (4.9) 27.7 (5.5) −0.97 −1.42 to −0.53 <0.001 −0.97 −1.42 to −0.53 <0.001 −4.8 −7.9 to -1.7 0.003
The measurements used in the analysis are those taken closest to the date of diagnosis or a random consultation date for the control population.
*Adjusted for age, gender, time period and social deprivation.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; BMI, body mass index.
Table 3 Results from multivariable logistic regression models outlining the frequency and adjusted ORs of symptoms and signs of pancreatic cancer and BTC presenting to primary care in the 2 years
prior to diagnosis compared with a control population without a cancer diagnosis
Biliary tract cancer Pancreatic cancer Controls Pancreatic cancer vs control Biliary tract cancer vs control
Pancreatic cancer vs biliary
tract cancer
Symptom (%) n=829 n=2790 n=17 192 OR* 95% CI p Value OR* 95% CI p Value OR* 95% CI p Value
Weight loss 46 (5.5) 294 (10.5) 302 (1.8) 6.6 5.54 to 7.86 <0.001 3.17 2.32 to 4.34 <0.001 2.00 1.49 to 2.68 <0.001
Abdominal pain 309 (37.3) 1225 (43.9) 1946 (11.3) 6.38 5.81 to 7.02 <0.001 4.68 4.01 to 5.47 <0.001 1.35 1.15 to 159 <0.001
Nausea and vomiting 126 (15.2) 463 (16.6) 978 (5.7) 3.43 3.00 to 3.91 <0.001 2.99 2.44 to 3.66 <0.001 1.12 0.89 to 1.39 0.33
Bloating 27 (3.3) 113 (4.1) 229 (1.3) 3.1 2.48 to 3.89 <0.001 2.35 1.57 to 3.53 <0.001 1.25 0.82 to 1.89 0.298
Dyspepsia 118 (14.2) 559 (20) 1597 (9.3) 2.56 2.30 to 2.85 <0.001 1.7 1.40 to 2.08 <0.001 1.51 1.23 to 1.86 <0.001
New onset diabetes 48 (5.8) 380 (13.6) 1037 (6) 2.46 2.16 to 2.80 <0.001 0.92 0.68 to 1.23 0.559 2.59 1.91 to 3.52 <0.001
Change in bowel habit 194 (23.4) 764 (27.4) 2557 (14.9) 2.17 1.98 to 2.39 <0.001 1.77 1.51 to 2.09 <0.001 1.23 1.04 to 1.46 0.014
Pruritus 91 (11) 147 (5.3) 526 (3.1) 1.73 1.43 to 2.10 <0.001 3.75 2.96 to 4.74 <0.001 0.44 0.34 to 0.59 <0.001
Lethargy 71 (8.6) 293 (10.5) 1308 (7.6) 1.42 1.25 to 1.61 <0.001 1.08 0.83 to 1.40 0.57 1.28 0.97 to 1.68 0.086
Back pain 111 (13.4) 446 (16) 2111 (12.3) 1.33 1.18 to 1.49 <0.001 1.01 0.82 to 1.26 0.913 1.28 1.01 to 1.61 0.037
Dysphagia 10 (1.2) 51 (1.8) 254 (1.5) 1.21 0.90 to 1.64 0.206 0.81 0.43 to 1.51 0.498 1.51 0.76 to 3.03 0.241
Non-cardiac chest pain 114 (13.8) 335 (12) 2055 (12) 1.02 0.91 to 1.16 0.699 1.19 0.97 to 1.46 0.092 0.86 0.70 to 1.07 0.175
Shoulder pain 47 (5.7) 137 (4.9) 1052 (6.1) 0.78 0.65 to 0.93 0.006 0.86 0.64 to 1.14 0.294 0.87 0.63 to 1.18 0.367
Jaundice * 358 (43.2) 860 (30.8) 36 (0.2) 246.00 172 to 351 <0.001 445 302 to 658 <0.001 0.57 0.48 to 0.66 <0.001
Models were adjusted for age, gender, time period and social deprivation (each symptom was assessed independently).
*Only 0.2% of controls were recorded with jaundice. However, among patients with PDAC and BCT, jaundice was highly prevalent occurring in 43.2% of patients with BTC and 30.8% of patients
with PDAC which lead to extremely large OR estimates.
BTC, biliary tract cancer; PDAC, pancreatic ductal adenocarcinoma.
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